Compare GOSS & MRCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GOSS | MRCC |
|---|---|---|
| Founded | 2015 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 101.2M | 100.1M |
| IPO Year | 2018 | 2011 |
| Metric | GOSS | MRCC |
|---|---|---|
| Price | $0.37 | $4.55 |
| Analyst Decision | Buy | |
| Analyst Count | 8 | 0 |
| Target Price | ★ $4.19 | N/A |
| AVG Volume (30 Days) | ★ 12.3M | 152.8K |
| Earning Date | 05-14-2026 | 03-05-2026 |
| Dividend Yield | N/A | ★ 7.83% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $48,471,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $147.82 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.32 | $4.11 |
| 52 Week High | $3.87 | $7.76 |
| Indicator | GOSS | MRCC |
|---|---|---|
| Relative Strength Index (RSI) | 28.37 | 40.07 |
| Support Level | $0.33 | $4.11 |
| Resistance Level | $0.60 | $4.97 |
| Average True Range (ATR) | 0.04 | 0.21 |
| MACD | 0.06 | 0.05 |
| Stochastic Oscillator | 30.41 | 34.62 |
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.
Monroe Capital Corp is a speciality finance company focused on providing financing to lower middle-market companies, in the United States and Canada. The company provides customized financing solutions focused on senior, unitranche, and junior secured debt and unsecured subordinated debt and equity, including equity co-investments in preferred and common stock and warrants. Its investment objective is to maximize the total return to its stockholders in the form of current income and capital appreciation through investment in senior secured, unitranche secured and junior secured debt and, to a lesser extent, unsecured subordinated debt and equity investments.